{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-003781","form_type":"8-K","ticker":"IVVD","cik":"0001832038","company_name":"Invivyd, Inc.","filed_at":"2025-01-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.154926+00:00","generated_at":"2026-05-28T05:32:20.715690+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Invivyd announces PEMGARDA neutralizes dominant SARS-CoV-2 variant XEC in vitro","bullets":["New data show PEMGARDA (pemivibart) maintains neutralizing activity against XEC, which with KP.3.1.1 accounts for 69% of U.S. variants per CDC.","Data submitted to FDA; update to PEMGARDA Fact Sheet for Healthcare Providers expected.","Pemivibart has shown consistent activity across 39 distinct SARS-CoV-2 variants over nearly three years.","Company does not anticipate meaningful change to neutralization if epitope remains intact as since Omicron BA.1."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-003781","json":"https://secwatch.observer/filing/0000950170-25-003781.json","markdown":"https://secwatch.observer/filing/0000950170-25-003781.md","text":"https://secwatch.observer/filing/0000950170-25-003781.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025003781/0000950170-25-003781-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1832038/000095017025003781/ivvd-20250110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T05:32:20.715690+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}